Verbatim response from Claude
FDA & Compounded GLP-1s: What Happened
The Short Version
The FDA declared the shortage of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) officially over, which triggered a legal requirement for compounding pharmacies to stop mass-producing copies of these drugs.
Key Deadlines
- Tirzepatide: Compounders were ordered to stop around March 2025
- Semaglutide: Deadline hit around April 2025
Who Is Still Operating Legally
503B outsourcing facilities (larger, FDA-registered compounders) had slightly longer timelines but are also largely required to wind down.
Still potentially legal:
- 503A compounding pharmacies can still make personalized compounded versions if a licensed prescriber writes a prescription with a specific patient need (like a unique dose or allergy accommodation) — but not mass production
- Hims & Hers fought this publicly but has been adjusting their offerings
- Ro, LifeMD, and similar telehealth platforms are shifting toward brand-name Ozempic/Wegovy/Zepbound
What I'd Recommend
Look at Ro, Hims & Hers, or Sesame for connecting with prescribers for brand-name GLP-1s, or check manufacturer savings programs like Novo Nordisk's assistance programs.
Always verify current status as this is evolving rapidly.